Éric Jourdan

3.2k total citations · 1 hit paper
60 papers, 2.1k citations indexed

About

Éric Jourdan is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Éric Jourdan has authored 60 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 24 papers in Hematology and 19 papers in Molecular Biology. Recurrent topics in Éric Jourdan's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Lymphoma Diagnosis and Treatment (9 papers). Éric Jourdan is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Lymphoma Diagnosis and Treatment (9 papers). Éric Jourdan collaborates with scholars based in France, United States and Italy. Éric Jourdan's co-authors include Christos C. Zouboulis, Mauro Picardo, A. Ravel, Annick Villet, Catherine Grosset, Éric Peyrin, Alessandro M. Vannucchi, Claire Harrison, Ruben A. Mesa and Francesco Passamonti and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Éric Jourdan

57 papers receiving 2.1k citations

Hit Papers

Safety and Efficacy of Fedratinib in Patients With Primar... 2015 2026 2018 2022 2015 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 340 citations Claire Harrison, Ruben A. Mesa et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Jourdan France 22 956 805 703 311 310 60 2.1k
Inge Romslo Norway 24 880 0.9× 313 0.4× 587 0.8× 126 0.4× 17 0.1× 103 2.0k
J P Kushner United States 19 990 1.0× 457 0.6× 698 1.0× 490 1.6× 25 0.1× 35 2.5k
Maria Palmisano United States 23 503 0.5× 135 0.2× 345 0.5× 109 0.4× 40 0.1× 85 1.5k
Nunziatina Laura Parrinello Italy 29 738 0.8× 336 0.4× 546 0.8× 77 0.2× 13 0.0× 95 2.0k
Amos Gaikwad United States 20 781 0.8× 282 0.4× 280 0.4× 160 0.5× 37 0.1× 49 1.6k
Ken Ohmine Japan 21 605 0.6× 210 0.3× 368 0.5× 75 0.2× 14 0.0× 82 1.4k
Suman Kambhampati United States 32 1.5k 1.6× 404 0.5× 849 1.2× 46 0.1× 14 0.0× 91 2.8k
Eduardo Magalhães Rego Brazil 33 2.7k 2.9× 307 0.4× 1.3k 1.8× 45 0.1× 26 0.1× 244 4.0k
Sandro Altamura Germany 28 1.0k 1.1× 708 0.9× 1.1k 1.5× 88 0.3× 7 0.0× 70 2.7k
Ketil Thorstensen Norway 18 232 0.2× 369 0.5× 611 0.9× 65 0.2× 22 0.1× 52 1.2k

Countries citing papers authored by Éric Jourdan

Since Specialization
Citations

This map shows the geographic impact of Éric Jourdan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Jourdan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Jourdan more than expected).

Fields of papers citing papers by Éric Jourdan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Jourdan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Jourdan. The network helps show where Éric Jourdan may publish in the future.

Co-authorship network of co-authors of Éric Jourdan

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Jourdan. A scholar is included among the top collaborators of Éric Jourdan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Jourdan. Éric Jourdan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suppan, Laurent, et al.. (2025). Epidemiology of prehospital traumatic cardiac arrest in Geneva: a retrospective cohort study. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine. 33(1). 169–169.
2.
Reboul, Jérôme, Anthony Boureux, Benoît Guibert, et al.. (2024). Effective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seq. NAR Genomics and Bioinformatics. 6(3). lqae117–lqae117.
3.
Barraco, Fiorenza, Jean‐Christophe Ianotto, Éric Jourdan, et al.. (2023). Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice. SHILAP Revista de lepidopterología. 4(3). 779–791. 2 indexed citations
4.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations
5.
Régny, Caroline, Lucie Obéric, Sandra Malak, et al.. (2019). PF482 CLINICAL EFFICACY OF THE RIBVD REGIMEN FOR REFRACTORY/RELAPSED (R/R) MANTLE CELL LYMPHOMA (MCL) PATIENTS: A RETROSPECTIVE STUDY OF THE LYSA GROUP. HemaSphere. 3(S1). 193–193. 1 indexed citations
6.
Carras, Sylvain, Delphine Sénécal, Jean-Philippe Jaı̈s, et al.. (2018). Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial. Clinical Lymphoma Myeloma & Leukemia. 18(3). 191–198. 7 indexed citations
7.
Misery, L., Éric Jourdan, Khaled Ezzedine, et al.. (2018). Development and validation of a new tool to assess the Burden of Sensitive Skin (BoSS). Journal of the European Academy of Dermatology and Venereology. 32(12). 2217–2223. 22 indexed citations
8.
Jourdan, Éric, et al.. (2017). Impact of Socio-Aesthetics as Supportive Care in A Large, Multi-Specialty Hospital. 2(1). 96–102. 3 indexed citations
9.
Jourdan, Éric, et al.. (2016). Assessment of a new biological complex efficacy on dysseborrhea, inflammation, and <em>Propionibacterium acnes</em> proliferation. Clinical Cosmetic and Investigational Dermatology. Volume 9. 233–239. 15 indexed citations
10.
11.
Zouboulis, Christos C., Éric Jourdan, & Mauro Picardo. (2013). Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. Journal of the European Academy of Dermatology and Venereology. 28(5). 527–532. 210 indexed citations
12.
Carillo, Serge, Laurent Henry, Éric Lippert, et al.. (2011). Nested High-Resolution Melting Curve Analysis. Journal of Molecular Diagnostics. 13(3). 263–270. 28 indexed citations
13.
Jourdan, Éric, Sophie Brun, Séverine Cunat, et al.. (2007). A novel mutation of the β‐globin gene promoter (−102 C>A) and pitfalls in family screening. American Journal of Hematology. 82(12). 1088–1090. 7 indexed citations
14.
Morschhauser, Franck, Stéphane Depil, Éric Jourdan, et al.. (2006). Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Annals of Oncology. 18(2). 370–375. 34 indexed citations
15.
Michaud, Mickaël, Éric Jourdan, Corinne Ravelet, et al.. (2004). Immobilized DNA Aptamers as Target-Specific Chiral Stationary Phases for Resolution of Nucleoside and Amino Acid Derivative Enantiomers. Analytical Chemistry. 76(4). 1015–1020. 101 indexed citations
16.
17.
Jourdan, Éric, et al.. (2003). Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder. Leukemia & lymphoma. 44(5). 889–890. 25 indexed citations
18.
Coiffier, Bertrand, Nicolas Mounier, Serge Bologna, et al.. (2002). Final results of the efficacy and safety of rasburicase (recombinant urate oxydase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study).. Blood. 100(11). 4 indexed citations
19.
Chimienti, Fabrice, Éric Jourdan, Alain Favier, & Michel Sève. (2001). Zinc resistance impairs sensitivity to oxidative stress in hela cells: protection through metallothioneins expression. Free Radical Biology and Medicine. 31(10). 1179–1190. 47 indexed citations
20.
Jourdan, Éric, et al.. (1961). L'essence de girofle de Madagascar. Technologie, distillation, emballage. Agritrop (Cirad). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inge Romslo Breakdown of academic impact, for papers by J P Kushner Breakdown of academic impact, for papers by Maria Palmisano Breakdown of academic impact, for papers by Nunziatina Laura Parrinello Breakdown of academic impact, for papers by Amos Gaikwad Breakdown of academic impact, for papers by Ken Ohmine Breakdown of academic impact, for papers by Suman Kambhampati Breakdown of academic impact, for papers by Eduardo Magalhães Rego Breakdown of academic impact, for papers by Sandro Altamura Breakdown of academic impact, for papers by Ketil Thorstensen
Rankless by CCL
2026